论文部分内容阅读
目的:评价双歧杆菌乳杆菌三联活菌片与三联疗法联用对幽门螺杆菌(Hp)性慢性胃炎患者的临床疗效。方法:选取2016年3月—2017年3月期间收治的慢性胃炎患者90例临床资料,采用随机数表法将其随机分为观察组和对照组(每组45例);对照组患者给予三联疗法(奥美拉唑肠溶胶囊、阿莫西林胶囊以及克拉霉素胶囊)治疗,观察组患者在对照组治疗基础上加用双歧杆菌乳杆菌三联活菌片治疗,比较两组患者治疗后的总有效率和临床症状评分值以及Hp根除情况。结果:观察组患者治疗后的总有效率为97.78%高于对照组为84.44%(P<0.05);治疗后两组患者的临床症状评分值低于治疗前(P<0.05);观察组患者的临床症状评分值低于对照组(P<0.05),Hp根除率为86.67%高于对照组为62.22%(P<0.05)。结论:双歧杆菌乳杆菌三联活菌片与三联疗法联用治疗Hp性慢性胃炎患者的临床疗效较为确切,有助于改善患者的临床症状和Hp的清除。
Objective: To evaluate the clinical efficacy of Lactobacillus bifidum triple active viable tablets combined with triple therapy in patients with Helicobacter pylori (Hp) chronic gastritis. Methods: The clinical data of 90 patients with chronic gastritis admitted from March 2016 to March 2017 were selected and randomly divided into observation group and control group (45 cases in each group) by random number table method. Patients in control group were treated with triple (Omeprazole enteric-coated capsules, amoxicillin capsules and clarithromycin capsules). The patients in the observation group were treated with Lactobacillus bifidum triple viable tablets on the basis of the control group. After the treatment, Total Efficacy and Clinical Symptom Score and Hp Eradication. Results: After treatment, the total effective rate of the observation group was 97.78% higher than that of the control group (84.44%, P <0.05). After treatment, the scores of clinical symptoms in both groups were lower than those before treatment (P <0.05) (P <0.05). The eradication rate of Hp was 86.67% higher than that of the control group (62.22%, P <0.05). Conclusion: The clinical efficacy of Lactobacillus Bifidum triple active viable tablet in combination with triple therapy in the treatment of Hp chronic gastritis patients is more exact, which will help to improve the clinical symptoms and Hp clearance.